Skip to content

Study · Non-randomized trial · 2019

4 results

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.

Blot K, Duchateau L, Lescrauwaet B, Liyanage N, Ray D, Mirakhur B, Vinik AI

Patient related outcome measures29 Oct 2019Cited by 2 (Europe PMC)

PMID31754316 (opens in a new tab)PMCIDPMC6825468 (opens in a new tab)DOI10.2147/prom.s219982 (opens in a new tab)PepBankPUB-31754316
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In NET patients with carcinoid syndrome, lanreotide increased C30 summary score response versus placebo (RR 2.42, P = 0.023).

    In plain wordsIn NET patients with carcinoid syndrome, lanreotide increased quality-of-life response versus placebo.

    Peptide
    Lanreotide
    Outcome
    IncreaseC30 summary score response
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Quality of life · Cancer
    Studied dose
    Dose not stated

    Measurements

    risk ratio (improvement on C30-SS)
    2.42
    lanreotide vs placebo

    Source sentences

    Summary
    Lanreotide patients were more likely to experience an improvement on the C30-SS (risk ratio [RR] 2.42; P=0.023), diarrhea burden (RR 2.85; P=0.005), and flushing burden (RR 1.39; P=0.31) compared to placebo patients.
    1 context sentence
    Summary · context
    The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-blind phase of the trial, specifically daily diarrhea and flushing symptoms, octreotide rescue use, and the EORTC QLQ-C30 and QLQ-GIN…
  2. 02HumanNon-randomized trialEfficacy outcome

    In NET patients with carcinoid syndrome, lanreotide increased diarrhea burden response versus placebo (RR 2.85, P = 0.005).

    In plain wordsIn NET patients with carcinoid syndrome, lanreotide increased diarrhea improvement responses versus placebo.

    Peptide
    Lanreotide
    Outcome
    IncreaseDiarrhea burden response
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Overall treatment effect · Cancer
    Studied dose
    Dose not stated

    Measurements

    risk ratio (improvement on diarrhea burden)
    2.85
    lanreotide vs placebo

    Source sentences

    Summary
    Lanreotide patients were more likely to experience an improvement on the C30-SS (risk ratio [RR] 2.42; P=0.023), diarrhea burden (RR 2.85; P=0.005), and flushing burden (RR 1.39; P=0.31) compared to placebo patients.
    1 context sentence
    Summary · context
    The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-blind phase of the trial, specifically daily diarrhea and flushing symptoms, octreotide rescue use, and the EORTC QLQ-C30 and QLQ-GIN…
  3. 03HumanNon-randomized trialEfficacy outcome

    In NET patients with carcinoid syndrome, flushing response did not differ significantly with lanreotide versus placebo (RR 1.39, P = 0.31).

    In plain wordsIn NET patients with carcinoid syndrome, flushing response did not differ significantly between lanreotide and placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeFlushing burden response
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Overall treatment effect · Cancer
    Studied dose
    Dose not stated

    Measurements

    risk ratio (improvement on flushing burden)
    1.39
    lanreotide vs placebo

    Source sentences

    Summary
    Lanreotide patients were more likely to experience an improvement on the C30-SS (risk ratio [RR] 2.42; P=0.023), diarrhea burden (RR 2.85; P=0.005), and flushing burden (RR 1.39; P=0.31) compared to placebo patients.
    1 context sentence
    Summary · context
    The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-blind phase of the trial, specifically daily diarrhea and flushing symptoms, octreotide rescue use, and the EORTC QLQ-C30 and QLQ-GIN…
  4. 04HumanNon-randomized trialEfficacy outcome

    In NET patients with carcinoid syndrome, lanreotide-treated patients had a higher probability of responding in at least one of the three domains than placebo patients (RR 1.48, P = 0.06).

    In plain wordsIn patients with carcinoid syndrome, lanreotide patients had a higher chance than placebo patients of responding in at least one domain.

    Peptide
    Lanreotide
    Outcome
    IncreaseResponse in at least one domain
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Overall treatment effect · Cancer
    Studied dose
    Dose not stated

    Measurements

    risk ratio (responder on at least one domain)
    1.48
    lanreotide vs placebo

    Source sentences

    Summary
    Lanreotide-treated patients have a higher probability of being a responder on at least one of the three domains of C30-SS, diarrhea burden, or flushing burden compared to placebo patients (RR 1.48; P=0.06).
    1 context sentence
    Summary · context
    The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-blind phase of the trial, specifically daily diarrhea and flushing symptoms, octreotide rescue use, and the EORTC QLQ-C30 and QLQ-GIN…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00774930

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Ipsenn = 115May 2009 to Dec 2015

Carcinoid Syndrome

Trial pageClinicalTrials.govUpdated 14 Oct 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.